No Data
Jiangsu Aidea Pharmaceutical (688488.SH): project cooperation development framework contract terminated with Pharma Block Sciences.
On April 8th, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its wholly-owned subsidiary Nanjing Aidea Pharmaceutical Technology Co., Ltd. signed the "Project Cooperation Development Framework Contract" (referred to as the "original framework contract") with Nanjing Pharma Block Sciences Co., Ltd. (hereinafter referred to as "Pharma Block Sciences" or "Party B") in August 2022 after friendly consultations. Both parties intend to jointly develop new drugs in the field of innovative targets and innovative compounds for 3CL protease inhibitors against the novel coronavirus pneumonia. Due to significant changes in the objective environment and market outlook of this project, both parties have reached a consensus through friendly negotiations to terminate the original framework contract and its annex in advance.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Aidea Pharmaceutical Gets Clinical Trial Approval for AD108 Injection
Jiangsu Aidea Pharmaceutical (688488.SH): AD108 injection has received the drug clinical trial approval notice.
On March 13, 2023, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its holding subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., received the "Notice of Drug Clinical Trial Approval" (referred to as the "Notice") issued by the National Medical Products Administration on March 12, 2025, approving the company to conduct Phase I clinical trials of the 2.2 class modified new drug AD108 injection. AD108 injection is a modified new drug (Chemical Drug class 2.2), with the active ingredient being human prorenin enzyme, specifically tissue type kallikrein-1 (KLK-1), which is a serine protease secreted by the kidneys.
What Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 27% Share Price Gain Is Not Telling You
